Portfolio News

 

   
March 31, 2014
Aptiv Exit
SV Life Sciences Fund IV notes that Icon acquired Aptiv from its owners, SV Life Sciences and others for $143.5m. Aptiv is a global development services company focused on enhancing clinical trial decision making and drug and device development through the design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk based monitoring.

Read more

Team - Kate Bingham
January 13, 2014
SV Life Sciences Announces Important Senior Leadership Promotions
SV Life Sciences Announces Important Senior Leadership Promotions BOSTON, MA, SAN FRANCISCO, CA, LONDON, UK (January 13, 2014): SV Life Sciences ("SVLS"), a leading international life sciences venture capital firm, today announced the appointments of Eugene Hill as Chairman, Paul LaViolette as Managing Partner and Chief Operating Officer, Tom Flynn as Managing Partner and Hamish Cameron as Operating Partner.

Read more

Team - James Garvey, Hamish Cameron, Tom Flynn, Eugene Hill, Paul LaViolette
January 2014
Thesan Pharmaceticals
SV Life Sciences V invested in Thesan Pharmaceuticals, a dermatology company focused on therapeutics for the treatment of atopic dermatitis and acne, as part of a $49m series B financing round.  ...

Read more

Team - Michael Ross
January 2014
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a seed loan financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
January 2014
AqueSys Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AqueSys, maker of proprietary implants for glaucoma-related vision loss, the world’s No. 2 cause of blindness as part of a $42m series D financing round.  ...

Read more

Team - David Guyer, David Milne
December 2013
CSA Medical
SV Life Sciences Fund V invested in CSA Medical, the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body, as part of a $16m financing round. ...

Read more

Team - Paul LaViolette, David Milne
December 2013
Rempex Pharmacuticals Exit
SV Life Sciences notes that on 04 December 2013 – The Medicines Company (NASDAQ: MDCO) entered in to a definitive agreement to purchase Rempex Pharmaceuticals for an upfront payment price of $140m and has agreed to pay Rempex equity holders milestone payments subsequent to closing. ...

Read more

Team - Michael Ross
November 2013
Sutro Biopharma
SV Life Science Fund V invested in Sutro Biopharma, an on-going development of low cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines, as part of a $26m series D financing round.  ...

Read more

Team - Michael Ross
November 2013
Juvaris - Investment
SV Life Sciences Fund IV invested in Juvaris, developing adjuvanted vaccines for infectious diseases as part of a $300k bridge loan financing round.  ...

Read more

Team - Bruce A Peacock, Michael Ross
November 2013
TopiVert Investment
SV Life Sciences notes that SV Life Science Fund V invested in TopiVert, focused on developing topical medicines for inflammatory diseases of the eye and gut as part of a £1m bridge funding round.   ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
November 2013
Cibiem Investment
SV Life Sciences notes that SV Life Science Fund V invested in Cibiem Inc. formerly Coridea NC1. Developer of CBM (Carotid Body Modulation) treatment of sympathetic nervous system-mediated diseases such as hypertension, heat failure, diabetes and renal failure as part of a $13m series B financing round. ...

Read more

Team - Paul LaViolette, David Milne
October 29, 2013
Delenex Therapeutics
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing.   Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/s, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round.

Read more

Team - Kate Bingham, Graham Boulnois
September 24, 2013
Ophthotech- IPO
SV Life Sciences Advisers notes that Ophthotech successfully listed on NASDAQ on 25 September 2013 NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech.

Read more

Team - David Guyer, Michael Ross
September 4, 2013
Transenterix merger with SafeStitch Medical (OTCBB: SFES)
SV Life Sciences Advisers notes that TransEnterix successfully merged with SafeStitch Medical on 4 September 2013. $30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--September 04, 2013 SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc.

Read more

Team - Paul LaViolette, David Milne

⇧ Back to top